Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.

Cancer chemotherapy and pharmacology - 1 Apr 2017

Ben Hassine Islem, Gharbi Hanene, Soltani Ismail, Teber Mouheb, Farrah Ahlem, Ben Hadj Othman Hind, Amouri Hassiba, Bellaaj Hatem, Lakhal Rayhane Ben, Romdhane Neila Ben, Abbes Salem, Menif Samia

Abstract excerpt

PURPOSE: Imatinib mesylate (IM) is considered as a highly effective therapy for chronic myeloid leukemia (CML) patients. However, a minority of patients fail to achieve optimal response due to impaired bioavailability of IM. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in IM uptake into CML cells. Genetic variants and/or hOCT1 expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Octamer Transcription Factor-1

Share to Protein Kinase Inhibitors

Share to Tunisia

Source

Identifiers

PMID: 28286932
DOI: 10.1007/s00280-017-3266-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.PMID 28286932Read ↗

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.Semantic proximity Read ↗

Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Semantic proximity Read ↗

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.Semantic proximity Read ↗

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.Semantic proximity Read ↗

hOCT 1 and resistance to imatinibSemantic proximity Read ↗

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.Semantic proximity Read ↗

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Semantic proximity Read ↗

Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemiaSemantic proximity Read ↗

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity Read ↗

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.Semantic proximity Read ↗

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.